Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events

J Thorac Oncol. 2021 Feb;16(2):183-186. doi: 10.1016/j.jtho.2020.11.029.

Authors

Roberto Ferrara¹, Corrado Campochiaro², Marina Chiara Garassino³

Affiliations

¹ Thoracic Oncology, Medical Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
² Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), San Raffaele Scientific Institute, Milan, Italy.
³ Thoracic Oncology, Medical Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: marina.garassino@gmail.com.

PMID: 33494923
DOI: 10.1016/j.jtho.2020.11.029

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Cytokines
Humans
Immune Checkpoint Inhibitors*
Lung Neoplasms*

Substances

Antibodies, Monoclonal, Humanized
Cytokines
Immune Checkpoint Inhibitors
tocilizumab